GBM progression and treatment resistance are linked to the GBM cellular epithelial–mesenchymal transition (EMT) mechanisms, where E-cadherin expression is reduced and N-cadherin expression is increased [109], resulting in the acquisition of a mesenchymal subtype that is more invasive and treatment resistant [104,106]. Here, CDH2 is linked to glioblastoma.